Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

BACKGROUND: The current randomized, double‐blind, phase 2 study assessed the efficacy and safety profile of a single intravenous administration of fosnetupitant, a neurokinin 1 receptor antagonist prodrug, for the prevention of chemotherapy‐induced nausea and vomiting in Japanese patients receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugawara, Shunichi, Inui, Naoki, Kanehara, Masashi, Morise, Masahiro, Yoshimori, Kozo, Kumagai, Toru, Fukui, Tomoya, Minato, Koichi, Iwashima, Akira, Takeda, Yuichiro, Kubota, Kaoru, Saeki, Toshiaki, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900104/
https://www.ncbi.nlm.nih.gov/pubmed/31381152
http://dx.doi.org/10.1002/cncr.32429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900104/
https://www.ncbi.nlm.nih.gov/pubmed/31381152
http://dx.doi.org/10.1002/cncr.32429

Ejemplares similares